Wisevoter
World

Ritlecitinib Study Revealed Hair Regrowth Patterns

The long-term ALLEGRO-LT trial evaluated how baseline scalp hair loss impacts regrowth success with ritlecitinib.

Updated on Oct. 6, 2026 in Allergies

Bold flat-color editorial illustration featuring a single stylized sprout growing from a metal plinth, symbolizing medical research on hair regrowth.
Researchers presenting findings from the ALLEGRO-LT study found that ritlecitinib treatment results in more significant hair regrowth for alopecia patients with lower initial hair loss. AI Illustration. Upload story photo >

Live Poll

Would you choose to remain on a long-term medical treatment if it successfully managed your condition?

Researchers presented findings from the long-term ALLEGRO-LT study, which assessed the efficacy of ritlecitinib in patients with alopecia. The study found that patients with less hair loss at the start of treatment experienced faster and more significant scalp hair regrowth.

Why it matters

The study aimed to determine the long-term effects of ritlecitinib based on varying levels of baseline hair loss severity. Understanding these patterns helps clinicians predict treatment outcomes for individuals across the spectrum of alopecia severity.

In the ALLEGRO-LT study, 76.3% of patients with low baseline hair loss achieved a SALT score of 20 or less after 6 months, compared to 22.5% of those with 95% to 100% loss. The trial measured efficacy across the spectrum of alopecia severity using a daily 50-mg dose.

The players

EADV Congress

This is an annual scientific meeting organized by the European Academy of Dermatology and Venereology to present advancements in the field.

The details

Participants were stratified into three groups by baseline SALT scores ranging from 25% to 100% hair loss and received a 200-mg daily loading dose for 4 weeks followed by 50 mg daily. While adverse events occurred in 89.7% of the cohort, serious adverse events were reported in 6.9% of patients, with no observed cases of venous thromboembolism.

Timeline

  1. 2023: Ritlecitinib became commercially available.

  2. 6 months: Primary assessment period for SALT score improvements.

  3. 12 months: Secondary assessment period for SALT score improvements.

  4. 5 years: Final follow-up assessment of study participants.

  5. October 2026: Findings presented at the EADV Congress in Vienna.

The Big Picture

The ALLEGRO-LT study serves as a critical benchmark for evaluating the long-term safety and hair regrowth efficacy of JAK inhibitors in alopecia patients. This data updates the efficacy and safety profile established during the initial commercial launch of ritlecitinib in 2023.

Patients considering ritlecitinib should discuss the likelihood of success based on their specific level of hair loss with a healthcare provider. The safety profile, including the incidence of serious infections, is a key consideration for individuals weighing the benefits of this daily medication.

The takeaway

The study confirms that baseline hair loss severity significantly influences the speed and extent of regrowth with ritlecitinib treatment. Prospective patients should consult a dermatologist to interpret these clinical findings in the context of their personal health history.

Further reading

For more information on dermatological treatments, visit the Allergies section.

Live Poll

Would you choose to remain on a long-term medical treatment if it successfully managed your condition?